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I.  General Information 
 
Unless otherwise noted, materials were either purchased from commercial suppliers and used 
as received or prepared via literature procedures.  NMe4SCF3 was synthesized according to a 
literature procedure1 and purified in THF/acetonitrile.  Solvents were deoxygenated and dried by 
thoroughly sparging with argon followed by passage through an activated column in a solvent 
purification system. 
All manipulations of air-sensitive materials were carried out in oven-dried glassware using 
standard Schlenk or glovebox techniques under N2 atmosphere.  Silicycle SiliaFlash® P60 silica gel 
(particle size 40-63 µm) was used for flash chromatography.  Analytical thin layer 
chromatography was conducted with glass TLC plates (silica gel 60 F254), and spots were 
visualized under UV light or after treatment with standard TLC stains. 
1H, 13C, 19F, and 31P NMR spectra were recorded on a Bruker Ascend 400 MHz, a Varian 300 
MHz, or a Varian 500 MHz with CHCl3 (1H, δ = 7.26) and CDCl3 (13C, δ = 77.0), CHDCl2 (1H, δ = 5.32) 
and CD2Cl2 (13C, δ = 53.5), or acetone-d6 (13C, δ = 29.8) as internal references.  Multiplicity and 
qualifier abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
br = broad). 
IR measurements were recorded on a Perkin Elmer Paragon 1000 spectrometer using thin films 
deposited on KBr plates. 
Mass spectral data were collected on an Agilent G6220A LC/MSD TOF mass spectrometer, or 
on an Agilent 5975C mass spectrometer with Triple-Axis Detector. 
X-ray crystallography studies were carried out at the Beckman Institute Crystallography 
Facility on a Bruker D8 Venture kappa duo photon 100 CMOS instrument (Mo Kα radiation).  
Structures were solved by direct methods2 and refined by full-matrix least-squares procedures on 
F2 (SHELXL-2013)2 using the OLEX2 interface.3  Hydrogen atoms were added at calculated 
positions.  Non-hydrogen atoms were refined anisotropically.  The crystals were mounted on a 
glass fiber or a nylon loop with Paratone N oil. 
Absorbance spectra were acquired on a Cary 50 UV-Vis spectrophotometer at room 
temperature. 
X-band EPR measurements were made with a Bruker EMX spectrometer at 40 K. 
Photolytic reactions were performed using 34 W Kessil H150 Blue LED lamps or a Luzchem 
LZC-4V photoreactor equipped with LZC-UVA lamps centered at approx. 350 nm or LZC-UVB 
lamps centered at approx. 300 nm.  If required, the temperature was maintained with an 
isopropanol bath cooled by an SP Scientific cryostat. 
Elemental analyses were performed by Midwest Microlab (Indianapolis, IN). 
 
 
  
 S–3 
II.  Photoinduced, Copper-Catalyzed Carbotrifluoromethylthiolation of Alkenes 
 
Preparation of a reaction mixture (liquid alkenes).  CuI and 2,2’-bis(diphenylphosphino)-1,1’-
binaphthyl (binap) were added to a 20-mL borosilicate glass vial that contained a magnetic stir bar.  
The vial was capped with a PTFE-lined septum cap (the joint was wrapped with electric tape), and 
then it was evacuated and backfilled with nitrogen (3 cycles).  Next, a solution of NMe4SCF3 in 
dry acetonitrile (prepared in a nitrogen-filled glovebox), ethyl bromodifluoroacetate, and the 
alkene were added in sequence via syringe, and the mixture was stirred at room temperature for 5 
min.  The vial was then detached from the Schlenk line, and the puncture holes in the septum 
were covered with vacuum grease and electric tape. 
Preparation of a reaction mixture (solid alkenes).  CuI, binap, and the alkene were added to a 
20-mL borosilicate glass vial that contained a magnetic stir bar.  The vial was capped with a PTFE-
lined septum cap (the joint was wrapped with electric tape), and then it was evacuated and 
backfilled with nitrogen (3 cycles).  Next, a solution of NMe4SCF3 in dry acetonitrile and ethyl 
bromodifluoroacetate were added in sequence via syringe, and the mixture was stirred at room 
temperature for 5 min.  The vial was then detached from the Schlenk line, and the puncture holes 
in the septum were covered with vacuum grease and electric tape. 
Preparation of a reaction mixture at room temperature (liquid electrophiles).  CuI, binap, 
and 4-vinylbiphenyl were added to a 20-mL borosilicate glass vial that contained a magnetic stir 
bar.  The vial was capped with a PTFE-lined septum cap (the joint was wrapped with electric 
tape), and then it was evacuated and backfilled with nitrogen (3 cycles).  Next, a solution of 
NMe4SCF3 in dry acetonitrile and the electrophile were added in sequence via syringe, and the 
mixture was stirred at room temperature for 5 min.  The vial was then detached from the Schlenk 
line, and the puncture holes in the septum were covered with vacuum grease and electric tape. 
Preparation of a reaction mixture at room temperature (solid electrophiles).  CuI, binap, 4-
vinylbiphenyl, and the electrophile were added to a 20-mL borosilicate glass vial that contained a 
magnetic stir bar.  The vial was capped with a PTFE-lined septum cap (the joint was wrapped 
with electric tape), and then it was evacuated and backfilled with nitrogen (3 cycles).  Next, a 
solution of NMe4SCF3 in dry acetonitrile was added in sequence via syringe, and the mixture was 
stirred at room temperature for 5 min.  The vial was then detached from the Schlenk line, and the 
puncture holes in the septum were covered with vacuum grease and electric tape. 
Preparation of a reaction mixture at low temperature (-40 to -10 °C).  CuI, binap, and 4-
vinylbiphenyl were added to an oven-dried 100-mL round-bottom flask.  The flask was sealed 
with a septum (the joint was wrapped with electric tape) and then put under a nitrogen 
atmosphere via three evacuate-refill cycles.  Next, a solution of NMe4SCF3 in dry acetonitrile was 
added, and the mixture was stirred at room temperature for 5 min.  The flask was then detached 
from the Schlenk line with a nitrogen-filled balloon and placed in an isopropanol bath cooled to 
certain temperature by an immersion cooler for 10 min.  A solution of the electrophile in dry 
acetonitrile was then slowly added to the reaction mixture for 5 min.  The balloon was removed 
from the flask, and the puncture holes in the septum were covered with vacuum grease and 
electric tape. 
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Figure S1.  Typical setups for copper-catalyzed three-component couplings upon blue LED 
irradiation. 
 
General Procedure: Irradiation of the reaction mixture with blue LED lamps.  For the 
reaction at room temperature, three 34-watt Kessil H150 blue-LED lamps were placed close to the 
vial, and the vial was irradiated for 10 h.  The temperature of the reaction mixture was 
maintained below 35 °C with a table fan.  A typical setup is shown in the top left picture. 
For the reaction at low temperature, the reaction flask and a magnetic stir bar were placed in a 
low-form hemispherical Dewar flask filled with isopropanol.  The blue-LED lamps were placed 
about 3 cm away from the flask, and the flask was irradiated for 36 h.  A typical setup is shown in 
the top right picture. 
Workup.  After irradiation, the reaction mixture was filtered through a short plug of silica gel 
(rinsed with ethyl acetate).  The resulting solution was concentrated under vacuum, and the 
product was isolated by flash column chromatography on silica gel. 
 
 
 
Ethyl 2,2-difluoro-5-phenyl-4-((trifluoromethyl)thio)pentanoate.  Table 2, entry 1.  The title 
compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 mmol), 
binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), allylbenzene (59 mg, 0.50 mmol), and 
ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified by column 
chromatography (1%→3% ethyl acetate/hexanes).  Colorless oil.  First run: 132 mg (77%).  
Second run: 130 mg (76%). 
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1H NMR (400 MHz, CDCl3) δ 7.37–7.28 (m, 3H), 7.23–7.16 (m, 2H), 4.33 (q, J = 7.1 Hz, 2H), 3.72–
3.75 (m, 1H), 3.16–3.05 (m, 2H), 2.57–2.48 (m, 2H), 1.35 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.5 (t, J = 32.4 Hz), 136.5, 130.5 (q, J = 308.2 Hz), 129.4, 128.7, 
127.3, 114.8 (dd, J = 254.2, 252.3 Hz), 63.3, 41.7, 40.4, 38.9 (t, J = 23.4 Hz), 13.8. 
19F NMR (282 MHz, CDCl3) δ -39.5 (s, 3F), -101.8 (dt, J = 264.0, 14.7 Hz, 1F), -106.0 (dt, J = 264.0, 
17.2 Hz, 1F). 
FT-IR (film): 3031, 2988, 1770, 1455, 1306, 1115, 756, 701 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H15F5O2SNa+: 365.0605, found: 365.0608. 
 
 
 
Ethyl 2,2-difluoro-4-((trifluoromethyl)thio)undecanoate.  Table 2, entry 2.  The title 
compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 mmol), 
binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), non-1-ene (63 mg, 0.50 mmol), and 
ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified by column 
chromatography (1%→3% ethyl acetate/hexanes).  Pale-yellow oil.  First run: 119 mg (68%).  
Second run: 124 mg (71%). 
1H NMR (400 MHz, CDCl3) δ 4.34 (q, J = 7.1 Hz, 2H), 3.46–3.39 (m, 1H), 2.67–2.42 (m, 2H), 1.88–
1.78 (m, 1H), 1.72–1.63 (m, 1H), 1.52–1.27 (m, 13H), 0.88 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) 163.6 (t, J = 32.3 Hz), 130.7 (q, J = 306.8 Hz), 114.8 (dd, J = 253.8, 
252.6 Hz), 63.2, 40.4 (t, J = 23.2 Hz), 39.6, 35.1, 31.7, 28.99, 28.95, 26.1, 22.6, 14.0, 13.8. 
19F NMR (282 MHz, CDCl3) δ -39.6 (s, 3F), -102.39 (ddd, J = 263.7, 18.1, 12.4 Hz, 1F), -106.44 (dt, J 
= 264.4, 17.3 Hz, 1F). 
FT-IR (film): 2931, 2860, 1772, 1468, 1377, 1308, 1120, 852 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H23F5O2SNa+: 373.1231, found: 373.1235. 
 
 
 
Ethyl 2,2-difluoro-5-phenoxy-4-((trifluoromethyl)thio)pentanoate.  Table 2, entry 3.  The 
title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), (allyloxy)benzene (67 mg, 0.50 
mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified 
by column chromatography (2%→4% ethyl acetate/hexanes).  Pale-yellow oil.  First run: 118 mg 
(66%).  Second run: 114 mg (64%). 
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1H NMR (400 MHz, CDCl3) δ 7.34–7.28 (m, 2H), 7.03–6.99 (m, 1H), 6.92–6.89 (m, 2H), 4.34–4.28 
(m, 3H), 4.16 (dd, J = 9.8, 5.5 Hz, 1H), 3.85–3.79 (m, 1H), 2.99–2.85 (m, 1H), 2.70–2.56 (m, 1H), 1.35 (t, 
J = 7.2 Hz, 3H). 
13C NMR (101 MHz, acetone-d6) δ 163.8 (t, J = 32.1 Hz), 159.0, 131.8 (q, J = 306.8 Hz), 130.4, 122.4, 
115.9 (dd, J = 252.4, 251.0 Hz), 115.5, 70.7, 64.0, 39.5, 37.4 (t, J = 23.6 Hz), 14.0. 
19F NMR (282 MHz, CDCl3) δ -40.4 (s, 3F), -103.2 (ddd, J = 265.7, 18.0, 12.7 Hz, 1F), -105.8 (dt, J = 
265.5, 17.1 Hz, 1F). 
FT-IR (film): 3065, 2944, 1682, 1760, 1600, 1498, 1243, 1118, 756 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H15F5O3SNa+: 381.0554, found: 381.0560. 
 
 
 
Ethyl 5-((tert-butoxycarbonyl)amino)-2,2-difluoro-4-((trifluoromethyl)thio)pentanoate.  
Table 2, entry 4.  The title compound was synthesized according to the General Procedure, using 
CuI (9.5 mg, 0.050 mmol), binap (31 mg, 0.050 mmol), tert-butyl allylcarbamate (79 mg, 0.50 mmol), 
NMe4SCF3 (131 mg, 0.75 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in 
acetonitrile (15 mL), and purified by column chromatography (7%→10% ethyl acetate/hexanes).  
Pale-yellow oil.  First run: 137 mg (72%).  Second run: 139 mg (73%). 
1H NMR (400 MHz, CDCl3) δ 5.01 (t, J = 6.3 Hz, 1H), 4.33 (q, J = 7.2 Hz, 2H), 3.62–3.50 (m, 2H), 
3.40–3.33 (m, 1H), 2.62–2.42 (m, 2H), 1.43 (s, 9H), 1.35 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.3 (t, J = 32.1 Hz), 155.8, 130.3 (q, J = 307.1 Hz), 114.6 (dd, J = 
253.4, 251.4 Hz), 80.1, 63.3, 44.6, 39.8, 37.4 (t, J = 23.8 Hz), 28.2, 13.7. 
19F NMR (282 MHz, CDCl3) δ -39.5 (s, 3F), -102.5 (dt, J = 265.8, 15.1 Hz, 1F), -105.7 (dt, J = 266.0, 
17.4 Hz, 1F). 
FT-IR (film): 3348, 2983, 1766, 1713, 1515, 1370, 1117, 857, 779 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C13H20F5NO4SNa+: 404.0925, found: 404.0923. 
 
 
 
Ethyl 2,2-difluoro-4-(p-tolyl)-4-((trifluoromethyl)thio)butanoate.  Table 2, entry 5.  The title 
compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 mmol), 
binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), 4-methylstyrene (59 mg, 0.50 mmol), 
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and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified by 
column chromatography (1%→3% ethyl acetate/hexanes).  Colorless oil.  First run: 144 mg (84%).  
Second run: 139 mg (81%). 
1H NMR (400 MHz, CDCl3) δ 7.23–7.11 (m, 4H), 4.59 (dd, J = 9.7, 5.0 Hz, 1H), 4.08–3.96 (m, 2H), 
3.01–2.77 (m, 2H), 2.34 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.1 (t, J = 32.1 Hz), 138.6, 134.8, 129.8 (q, J = 309.1 Hz), 129.6, 
127.5, 114.1 (dd, J = 253.5, 251.4 Hz), 63.1, 42.8–42.7 (m), 41.3 (t, J = 23.9 Hz), 21.1, 13.6. 
19F NMR (282 MHz, CDCl3) δ -40.4 (s, 3F), -102.3 (dt, J = 265.8, 13.9 Hz, 1F), -105.6 (ddd, J = 265.9, 
17.5, 14.2 Hz, 1F). 
FT-IR (film): 2988, 2928, 1771, 1515, 1304, 1114, 1021, 788 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H15F5O2SNa+: 365.0605, found: 365.0604. 
 
 
 
Ethyl 2,2-difluoro-4-(4-methoxyphenyl)-4-((trifluoromethyl)thio)butanoate.  Table 2, entry 
6.  The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 
0.050 mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), 4-methoxylstyrene (67 
mg, 0.50 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and 
purified by column chromatography (1%→3% ethyl acetate/hexanes).  Colorless oil.  First run: 
154 mg (86%).  Second run: 166 mg (93%). 
1H NMR (500 MHz, CDCl3) δ 7.25–7.22 (m, 2H), 6.88–6.85 (m, 2H), 4.60 (dd, J = 10.0, 4.8 Hz, 1H), 
4.08–3.98 (m, 2H), 3.80 (s, 3H), 3.00–2.78 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 163.0 (t, J = 32.1 Hz), 159.7, 129.8 (q, J = 308.9 Hz), 129.5, 128.9, 
114.2, 114.1 (dd, J = 254.1, 252.1 Hz), 63.1, 55.2, 42.6–42.5 (m), 41.3 (t, J = 23.8 Hz), 13.6. 
19F NMR (282 MHz, CDCl3) δ -40.4 (s, 3F), -102.2 (ddd, J = 265.7, 14.7, 12.8 Hz, 1F), -105.9 (ddd, J 
= 265.7, 17.9, 13.9 Hz, 1F). 
FT-IR (film): 2989, 2842, 1771, 1613, 1515, 1306, 1114, 1035, 840 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H15F5O3SNa+: 381.0554, found: 381.0557. 
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Ethyl 2,2-difluoro-4-(4-(trifluoromethyl)phenyl)-4-((trifluoromethyl)thio)butanoate.  Table 
2, entry 7.  The title compound was synthesized according to the General Procedure, using CuI 
(9.5 mg, 0.050 mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), 4-
trifluoromethylstyrene (86 mg, 0.50 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in 
acetonitrile (15 mL), and purified by column chromatography (1%→3% ethyl acetate/hexanes).  
Pale-yellow oil.  First run: 182 mg (92%).  Second run: 178 mg (90%). 
1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 4.68 (dd, J = 9.0, 5.6 
Hz, 1H), 4.15–4.06 (m, 2H), 2.95–2.80 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 162.9 (t, J = 31.9 Hz), 142.6, 130.8 (q, J = 32.9 Hz), 129.6 (q, J = 309.0 
Hz), 128.1, 125.9 (q, J = 3.8 Hz), 123.7 (q, J = 273.0 Hz), 113.9 (dd, J = 254.2, 253.4 Hz), 63.3, 42.34–
42.25 (m), 40.8 (t, J = 24.0 Hz), 13.7. 
19F NMR (282 MHz, CDCl3) δ -40.3 (s, 3F), -62.9 (s, 3F), -103.2 (dt, J = 267.4, 14.8 Hz, 1F), -104.9 
(dt, J = 267.5, 15.3 Hz, 1F). 
FT-IR (film): 2991, 1771, 1621, 1422, 1327, 1116, 1020, 850 cm–1. 
MS (EI) m/z (M)+ calcd for C14H12F8O2S+: 396.0, found: 396.1. 
 
 
 
Ethyl 4-([1,1'-biphenyl]-4-yl)-2,2-difluoro-4-((trifluoromethyl)thio)butanoate.  Table 2, entry 
8.  The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 
0.050 mmol), binap (31 mg, 0.050 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), NMe4SCF3 (131 mg, 
0.75 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and 
purified by column chromatography (1%→3% ethyl acetate/hexanes).  White solid.  First run: 
167 mg (82%).  Second run: 171 mg (85%). 
Gram-scale reaction: CuI (76 mg, 0.40 mmol) and binap (248 mg, 0.40 mmol), and 4-
vinylbiphenyl (720 mg, 4.0 mmol), were added to an oven-dried 250-mL round-bottom flask that 
contained a magnetic stir bar.  The flask was capped with a PTFE-lined septum cap (the joint was 
wrapped with electric tape), and then it was evacuated and backfilled with nitrogen (3 cycles).  
Next, a solution of NMe4SCF3 (1.05 g, 6.0 mmol) in dry acetonitrile (120 mL) and ethyl 
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bromodifluoroacetate (0.77 mL, 6.0 mmol) were added in sequence via syringe, and the mixture 
was stirred at room temperature for 5 min.  The flask was then detached from the Schlenk line, 
and the puncture holes in the septum were covered with vacuum grease and electric tape.  Three 
34-watt Kessil H150 blue-LED lamps were placed close to the flask, and the flask was irradiated for 
10 h.  The temperature of the reaction mixture was maintained below 35 °C with a table fan.  
After irradiation, the reaction mixture was filtered through a short plug of silica gel (rinsed with 
ethyl acetate).  The resulting solution was concentrated under vacuum, and the product was 
isolated by flash column chromatography (1%→3% ethyl acetate/hexanes) on silica gel to give a 
pale-yellow solid.  First run: 1.34 g (83%).  Second run: 1.31 g (81%). 
1H NMR (500 MHz, CDCl3) δ 7.61–7.57 (m, 4H), 7.48–7.44 (m, 2H), 7.42–7.36 (m, 3H), 4.69 (dd, J 
= 9.7, 4.9 Hz, 1H), 4.09–4.00 (m, 2H), 3.07–2.86 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 163.1 (t, J = 32.1 Hz), 141.6, 140.1, 136.9, 129.8 (q, J = 308.9 Hz), 
128.8, 128.0, 127.7, 127.5, 127.0, 114.1 (dd, J = 253.6, 251.6 Hz), 63.1, 42.7–42.6 (m), 41.2 (t, J = 23.9 
Hz), 13.7. 
19F NMR (282 MHz, CDCl3) δ -40.3 (s, 3F), -102.2 (dt, J = 266.1, 13.8 Hz, 1F), -105. 6 (ddd, J = 
266.1, 17.4, 14.2 Hz, 1F). 
FT-IR (film): 3032, 2988, 1770, 1488, 1304, 1114, 848, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C19H17F5O2SNa+: 427.0762, found: 427.0758. 
 
 
 
5-Benzyl 1-ethyl 2,2-difluoro-4-((trifluoromethyl)thio)pentanedioate.  Table 2, entry 9.  The 
title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), benzyl acrylate (81 mg, 0.50 
mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL) at -10 °C for 24 
h, and purified by column chromatography (2%→5% ethyl acetate/hexanes).  Colorless oil.  First 
run: 160 mg (83%).  Second run: 166 mg (86%). 
1H NMR (400 MHz, CDCl3) δ 7.42–7.33 (m, 5H), 5.26–5.17 (m, 2H), 4.32 (q, J = 7.1 Hz, 2H), 4.09 
(dd, J = 9.8, 4.3 Hz, 1H), 3.09–2.95 (m, 1H), 2.72–2.58 (m, 1H), 1.35 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 162.8 (t, J = 31.9 Hz), 134.5, 129.6 (q, J = 309.5 Hz), 128.65, 
128.62, 128.4, 113.8 (t, J = 252.9 Hz), 68.4, 63.5, 39.4–39.3 (m), 37.5 (t, J = 24.0 Hz), 13.8. 
19F NMR (282 MHz, CDCl3) δ -40.4 (s, 3F), -104.2–-106.5 (m, 2F). 
FT-IR (film): 2989, 1748, 1457, 1379, 1307, 1112, 758, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C15H15F5O4SNa+: 409.0503, found: 409.0508. 
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Ethyl 2,2-difluoro-4-phenyl-4-((trifluoromethyl)thio)pentanoate.  Table 2, entry 10.  The 
title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), α-methylstyrene (59 mg, 0.50 
mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified 
by column chromatography (1%→3% ethyl acetate/hexanes).  Pale-yellow oil.  First run: 145 mg 
(85%).  Second run: 148 mg (87%). 
1H NMR (500 MHz, CDCl3) δ 7.54–7.51 (m, 2H), 7.40–7.36 (m, 2H), 7.33–7.30 (m, 1H), 3.93–3.79 
(m, 2H), 3.26 (dt, J = 20.2, 14.9 Hz, 1H), 3.00 (dt, J = 15.0, 13.1 Hz, 1H), 2.19 (s, 3H), 1.21 (t, J = 7.2 Hz, 
3H). 
13C NMR (126 MHz, CDCl3) δ 163.2 (dd, J = 32.4, 31.7 Hz), 139.7, 129.7 (q, J = 310.6 Hz), 128.44, 
128.39, 126.8, 114.4 (dd, J = 255.3, 251.4 Hz), 63.0, 53.3 (d, J = 5.7 Hz), 46.4–46.0 (m), 26.0, 13.6. 
19F NMR (282 MHz, CDCl3) δ -36.4 (s, 3F), -96.4 (dt, J = 263.9, 13.9 Hz, 1F), -101.7–-102.8 (m, 1F). 
FT-IR (film): 3063, 2992, 1770, 1448, 1300, 1120, 1035, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H15F5O2SNa+: 365.0605, found: 365.0602. 
 
 
 
Ethyl 4-cyclohexyl-2,2-difluoro-4-phenyl-4-((trifluoromethyl)thio)butanoate.  Table 2, entry 
11.  The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 
0.050 mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), (1-
cyclohexylvinyl)benzene (93 mg, 0.50 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) 
in acetonitrile (15 mL), and purified by column chromatography (1%→3% ethyl acetate/hexanes).  
Pale-yellow oil.  First run: 204 mg (99%).  Second run: 196 mg (97%). 
1H NMR (500 MHz, CDCl3) δ 7.52–7.49 (m, 2H), 7.36–7.33 (m, 2H), 7.31–7.28 (m, 1H), 4.21–4.15 
(m, 2H), 3.35–3.28 (m, 2H), 2.17–2.09 (m, 2H), 1.89–1.83 (m, 1H), 1.79–1.71 (m, 2H), 1.63–1.57 (m, 
1H), 1.33–1.20 (m, 5H), 0.99–0.83 (m, 2H), 0.78–0.70 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 164.0 (t, J = 32.4 Hz), 137.4, 130.2 (q, J = 310.3 Hz), 128.1, 127.69, 
127.66, 115.4 (t, J = 253.2 Hz), 63.1, 62.9 (t, J = 2.3 Hz), 46.0, 40.7–40.3 (m), 28.4, 28.1, 26.42, 26.37, 25.9, 
13.6. 
19F NMR (282 MHz, CDCl3) δ -34.6 (s, 3F), -98.3–-98.4 (m, 2F). 
FT-IR (film): 2937, 2858, 1812, 1770, 1446, 1305, 1097, 702 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C19H23F5O2SNa+: 433.1231, found: 433.1236. 
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Ethyl 2,2-difluoro-4-methyl-5-phenyl-4-((trifluoromethyl)thio)pentanoate.  Table 2, entry 12.  
The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), methallylbenzene (66 mg, 0.50 
mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified 
by column chromatography (1%→3% ethyl acetate/hexanes).  Colorless oil.  First run: 119 mg 
(67%).  Second run: 124 mg (70%). 
1H NMR (400 MHz, CDCl3) δ 7.36–7.30 (m, 3H), 7.26–7.23 (m, 2H), 4.34 (q, J = 7.1 Hz, 2H), 3.21–
3.13 (m, 2H), 2.72–2.62 (m, 2H), 1.59 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.8 (t, J = 32.4 Hz), 134.8, 131.2, 130.5 (q, J = 309.7 Hz), 128.2, 
127.4, 115.3 (dd, J = 254.6, 253.2 Hz), 63.3, 52.1, 47.6, 43.2 (t, J = 22.6 Hz), 26.1, 13.7. 
19F NMR (282 MHz, CDCl3) δ -34.8 (s, 3F), -99.7 (dt, J = 263.1, 16.3 Hz, 1F), -101.3 (dt, J = 263.0, 
18.1 Hz, 1F). 
FT-IR (film): 2987, 1770, 1496, 1455, 1308, 1103, 1033, 703 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C15H17F5O2SNa+: 379.0762, found: 379.0759. 
 
 
 
Ethyl 2,2-difluoro-3-methyl-4-phenyl-4-((trifluoromethyl)thio)butanoate.  Table 2, entry 13.  
The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), β-methylstyrene (59 mg, 0.50 
mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and purified 
by column chromatography (1%→3% ethyl acetate/hexanes).  Pale-yellow oil.  First run: 125 mg 
(73%), 10.7:1 d.r.  Second run: 121 mg (71%), 10.9:1 d.r. 
1H NMR (400 MHz, CDCl3) δ 7.40–7.28 (m, 5H), 4.65–4.62 (m, 1H), 4.32–4.12 (m, 2H), 3.08–2.78 
(m, 1H), 1.37–1.29 (m, 3H), 1.26–1.10 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.6 (t, J = 40.6 Hz), 163.3 (t, J = 40.4 Hz), 139.5, 130.2 (q, J = 308.3 
Hz), 128.6, 128.1, 128.0, 116.0 (t, J = 256.3 Hz), 115.9 (dd, J = 257.3, 255.7 Hz), 63.2, 63.1, 48.9–48.8, 
47.9, 44.3 (t, J = 22.2 Hz), 43.1 (t, J = 21.9 Hz), 13.8, 13.7, 10.2 (t, J = 4.4 Hz), 9.8 (t, J = 4.4 Hz). 
19F NMR (282 MHz, CDCl3) δ -40.3 (s), -40.7 (s), -107.3 (dd, J = 262.0, 13.3 Hz), -108.1 (dd, J = 
262.5, 14.4 Hz), -111.0 (dd, J = 263.5, 14.8 Hz), -111.1 (dd, J = 262.0, 14.2 Hz). 
FT-IR (film): 2989, 1773, 1455, 1303, 1116, 1040, 758, 700 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C14H15F5O2SNa+: 365.0605, found: 365.0604. 
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Ethyl 2,2-difluoro-3-methyl-4-phenyl-4-((trifluoromethyl)thio)pentanoate.  Table 2, entry 14.  
The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), NMe4SCF3 (131 mg, 0.75 mmol), α,β-dimethylstyrene (66 mg, 
0.50 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) in acetonitrile (15 mL), and 
purified by column chromatography (1%→2% ethyl acetate/hexanes).  Pale-yellow oil.  First run: 
103 mg (58%).  Second run: 99 mg (56%). 
1H NMR (400 MHz, CDCl3) δ 7.60–7.57 (m, 2H), 7.35–7.30 (m, 2H), 7.29–7.25 (m, 1H), 3.88–3.80 
(m, 1H), 3.75–3.67 (m, 1H), 3.30–3.18 (m, 1H), 2.10 (s, 3H), 1.41–1.39 (m, 3H), 1.18 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.2 (t, J = 32.2 Hz), 141.3, 129.8 (q, J = 309.6 Hz), 128.1, 127.9, 
127.8, 115.9 (dd, J = 260.3, 252.8 Hz), 62.8, 58.9 (d, J = 4.1 Hz), 47.1–46.6, 22.24–22.19, 13.6, 10.2 (dd, J 
= 7.1, 3.9 Hz). 
19F NMR (282 MHz, CDCl3) δ -35.7 (s, 3F), -99.8 (dd, J = 263.5, 11.5 Hz, 1F), -109.1 (dd, J = 263.7, 
18.8 Hz, 1F). 
FT-IR (film): 2998, 1770, 1448, 1298, 1113, 1038, 757, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C15H17F5O2SNa+: 379.0762, found: 379.0763. 
 
 
 
Ethyl 2,2-difluoro-4-((8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthren-3-yl)-4-((trifluoromethyl)thio)butanoate.  Table 2, entry 15.  The 
title compound was synthesized according to the General Procedure, using CuI (5.7 mg, 0.030 
mmol), binap (18.7 mg, 0.030 mmol), NMe4SCF3 (78.8 mg, 0.45 mmol), (8R,9S,13S,14S)-13-methyl-3-
vinyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (84.0 mg, 0.30 
mmol), and ethyl bromodifluoroacetate (91.4 mg, 0.45 mmol) in anhydrous acetonitrile (9 mL), and 
purified by column chromatography (10%→16% ethyl acetate/hexanes).  Colorless oil.  First run: 
142 mg (94%), 1:1 d.r.  Second run: 138 mg (91%), 1:1 d.r. 
1H NMR (400 MHz, CDCl3) δ 7.26–7.24 (m, 1H), 7.08–7.05 (m, 1H), 7.02–7.00 (m, 1H), 4.54 (dd, J 
= 9.5, 5.1 Hz, 1H), 4.09–3.96 (m, 2H), 3.00–2.77 (m, 4H), 2.50 (dd, J = 18.7, 8.7 Hz, 1H), 2.44–2.34 (m, 
1H), 2.29–2.24 (m, 1H), 2.18–1.92 (m, 4H), 1.67–1.38 (m, 6H), 1.24–1.20 (m, 3H), 0.90 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 220.6, 163.1 (t, J = 32.2 Hz), 163.0 (t, J = 32.3 Hz), 140.2, 137.15, 
137.12, 135.19, 135.17, 129.8 (q, J = 309.2 Hz), 128.0, 127.9, 125.9, 125.8, 124.7, 124.6, 116.6–111.6, 63.0, 
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50.4, 47.8, 44.2, 42.6–42.5, 41.33 (t, J = 23.8 Hz), 41.27 (t, J = 23.8 Hz), 37.9, 35.7, 31.5, 29.21, 29.18, 
26.26, 26.25, 25.5, 21.5, 13.7, 13.6. 
19F NMR (282 MHz, CDCl3) δ -40.41 (s), -40.43 (s), -102.1–-103.2 (m), -104.8–-105.9 (m). 
FT-IR (film): 2933, 2866, 1769, 1739, 1499, 1302, 1009, 854, 781 cm–1. 
MS (ESI) m/z (M+H)+ calcd for C25H30F5O3S+: 505.1830, found: 505.1829. 
 
 
 
Ethyl 4-([1,1'-biphenyl]-4-yl)-4-((trifluoromethyl)thio)butanoate.  Table 3, entry 1.  The title 
compound was synthesized according to the General Procedure at low temperature.  To the 
reaction mixture of CuI (19 mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 mg, 0.50 
mmol), and NMe4SCF3 (131 mg, 0.75 mmol) in acetonitrile (56 mL) at -40 °C was added ethyl 2-
bromoacetate (125 mg, 0.75 mmol) in acetonitrile (4 mL).  The product was purified by column 
chromatography (3%→6% ethyl acetate/hexanes).  White solid.  First run: 110 mg (60%).  
Second run: 101 mg (55%). 
1H NMR (400 MHz, CDCl3) δ 7.60–7.56 (m, 4H), 7.47–7.42 (m, 2H), 7.38–7.34 (m, 3H), 4.44–4.39 
(m, 1H), 4.12 (q, J = 7.1 Hz, 2H), 2.43–2.27 (m, 4H), 1.25 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.2, 141.1, 140.3, 138.6, 130.4 (q, J = 308.6 Hz), 128.8, 127.8, 127.6, 
127.5, 127.0, 60.7, 48.4, 31.7, 31.6, 14.2. 
19F NMR (282 MHz, CDCl3) δ -39.8 (s, 3F). 
FT-IR (film): 2927, 1732, 1487, 1376, 1149, 1113, 756, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C19H19F3O2SNa+: 391.0950, found: 391.0949. 
 
 
 
4-([1,1'-Biphenyl]-4-yl)-1-phenyl-4-((trifluoromethyl)thio)butan-1-one.  Table 3, entry 2.  
The title compound was synthesized according to the General Procedure at low temperature.  To 
the reaction mixture of CuI (19 mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 mg, 
0.50 mmol), and NMe4SCF3 (131 mg, 0.75 mmol) in acetonitrile (56 mL) at -10 °C was added 2-
bromoacetophenone (149 mg, 0.75 mmol) in acetonitrile (4 mL).  The product was purified by 
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column chromatography (5%→8% ethyl acetate/hexanes).  White solid.  First run: 154 mg (77%).  
Second run: 158 mg (79%). 
1H NMR (400 MHz, CDCl3) δ 7.91–7.87 (m, 2H), 7.60–7.54 (m, 5H), 7.48–7.39 (m, 6H), 7.38–7.34 
(m, 1H), 4.51 (dd, J = 8.8, 6.9 Hz, 1H), 3.05 (t, J = 7.1 Hz, 2H), 2.57–2.38 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 198.5, 141.0, 140.3, 139.0, 136.5, 133.3, 130.4 (q, J = 308.6 Hz), 128.8, 
128.6, 127.9, 127.8, 127.6, 127.5, 127.0, 48.61–48.56, 35.8, 30.7. 
19F NMR (282 MHz, CDCl3) δ -39.7 (s, 3F). 
FT-IR (film): 2924, 1678, 1448, 1408, 1228, 1147, 1109, 691 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C23H19F3OSNa+: 423.1001, found: 423.1006. 
 
 
 
Diethyl 2-(2-([1,1'-biphenyl]-4-yl)-2-((trifluoromethyl)thio)ethyl)malonate.  Table 3, entry 3.  
The title compound was synthesized according to the General Procedure at low temperature.  To 
the reaction mixture of CuI (19 mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 mg, 
0.50 mmol), and NMe4SCF3 (131 mg, 0.75 mmol) in acetonitrile (56 mL) at -40 °C was added diethyl 
2-bromomalonate (179 mg, 0.75 mmol) in acetonitrile (4 mL).  The product was purified by 
column chromatography (5%→7% ethyl acetate/hexanes).  Colorless oil.  First run: 127 mg (58%).  
Second run: 136 mg (62%). 
1H NMR (400 MHz, CDCl3) δ 7.61–7.56 (m, 4H), 7.47–7.42 (m, 2H), 7.39–7.34 (m, 3H), 4.44 (dd, J 
= 9.4, 6.7 Hz, 1H), 4.29–4.10 (m, 4H), 3.35 (dd, J = 8.5, 6.3 Hz, 1H), 2.70–2.53 (m, 2H), 1.29 (t, J = 7.2 
Hz, 3H), 1.24 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.4, 141.3, 140.3, 137.9, 130.2 (q, J = 308.8 Hz), 128.8, 127.9, 127.7, 
127.6, 127.0, 61.8, 49.7, 46.9, 35.3, 14.02, 13.96. 
19F NMR (282 MHz, CDCl3) δ -39.9 (s, 3F). 
FT-IR (film): 2984, 1748, 1732, 1487, 1371, 1152, 1113, 755, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C22H23F3O4SNa+: 463.1161, found: 463.1167. 
 
 
 
Methyl 4-([1,1'-biphenyl]-4-yl)-2-methyl-4-((trifluoromethyl)thio)butanoate.  Table 3, entry 
4.  The title compound was synthesized according to the General Procedure at low temperature.  
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To the reaction mixture of CuI (19 mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 
mg, 0.50 mmol), and NMe4SCF3 (262 mg, 1.50 mmol) in acetonitrile (56 mL) at -10 °C was added 
methyl 2-bromopropanoate (251 mg, 1.50 mmol) in acetonitrile (4 mL).  The product was purified 
by column chromatography (4%→6% ethyl acetate/hexanes).  Colorless oil.  First run: 128 mg 
(70%), 1.3:1 d.r.  Second run: 132 mg (72%), 1.3:1 d.r. 
1H NMR (400 MHz, CDCl3) δ 7.62–7.57 (m, 4H), 7.47–7.43 (m, 2H), 7.41–7.34 (m, 3H), 4.48–4.41 
(m, 1H), 3.70 (s, 1.28H), 3.62 (s, 1.72H), 2.59–2.38 (m, 2H), 2.10–2.01 (m, 1H), 1.24–1.19 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.8, 175.7, 141.03, 141.00, 140.33, 140.31, 138.7, 138.6, 130.34 (q, J 
= 308.6 Hz), 130.30 (q, J = 308.6 Hz), 128.8, 127.85, 127.82, 127.6, 127.53, 127.48, 127.01, 51.78, 51.76, 
47.41–47.35 (m), 47.10–47.05 (m), 40.3, 39.7, 37.2, 17.6, 16.8. 
19F NMR (282 MHz, CDCl3) δ -39.76, -39.79 (s, 3F). 
FT-IR (film): 3031, 2953, 1737, 1488, 1265, 1113, 756, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C19H19F3O2SNa+: 391.0950, found: 391.0952. 
 
 
 
Methyl 4-([1,1'-biphenyl]-4-yl)-2-(methoxymethyl)-4-((trifluoromethyl)thio)butanoate.  
Table 3, entry 5.  The title compound was synthesized according to the General Procedure at low 
temperature.  To the reaction mixture of CuI (19 mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-
vinylbiphenyl (90 mg, 0.50 mmol), and NMe4SCF3 (262 mg, 1.50 mmol) in acetonitrile (56 mL) at -10 
°C was added methyl 2-bromo-3-methoxypropanoate (296 mg, 1.50 mmol) in acetonitrile (4 mL).  
The product was purified by column chromatography (4%→6% ethyl acetate/hexanes).  Colorless 
oil.  First run: 147 mg (74%). 1.8:1 d.r.  Second run: 139 mg (70%). 1.8:1 d.r. 
1H NMR (400 MHz, CDCl3) δ 7.63–7.57 (m, 4H), 7.47–7.34 (m, 5H), 4.51–4.46 (m, 1H), 3.74 (s, 
1.06H), 3.62 (s, 1.94H), 3.60–3.47 (m, 2H), 3.34 (s, 1.93H), 3.28 (s, 1.07H), 2.85–2.79 (m, 0.63H), 2.61–
2.55 (m, 0.35H), 2.54–2.44 (m, 1H), 2.29–2.20 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 173.4, 173.3, 141.1, 141.0, 140.33, 140.28, 138.9, 138.2, 130.3 (q, J = 
308.6 Hz), 130.2 (q, J = 308.8 Hz), 128.8, 127.92, 127.87, 127.6, 127.48, 127.46, 127.0, 72.9, 72.7, 59.0, 
58.9, 51.95, 51.89, 47.62–47.56 (m), 47.1–47.0 (m), 43.6, 43.4, 35.43, 35.39. 
19F NMR (282 MHz, CDCl3) δ -39.80, -39.84 (s, 3F). 
FT-IR (film): 3031, 2952, 1738, 1487, 1214, 1113, 840, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C20H21F3O3SNa+: 421.1056, found: 421.1060. 
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2-(2-([1,1'-Biphenyl]-4-yl)-2-((trifluoromethyl)thio)ethyl)-1-indanone.  Table 3, entry 6.  The 
title compound was synthesized according to the General Procedure at low temperature.  To the 
reaction mixture of CuI (19 mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 mg, 0.50 
mmol), and NMe4SCF3 (131 mg, 0.75 mmol) in acetonitrile (56 mL) at -10 °C was added 2-bromo-1-
indanone (158 mg, 0.75 mmol) in acetonitrile (4 mL).  The product was purified by column 
chromatography (5%→8% ethyl acetate/hexanes).  Pale-yellow oil.  First run: 146 mg (71%), 1.3 
d.r.  Second run: 140 mg (68%), 1.3:1 d.r. 
1H NMR (400 MHz, CDCl3) δ 7.76–7.74 (m, 1H), 7.63–7.56 (m, 5H), 7.51–7.41 (m, 5H), 7.40–7.34 
(m, 2H), 4.88 (dd, J = 8.6, 7.4 Hz, 0.57H), 4.63 (dd, J = 11.0, 5.4 Hz, 0.43H), 3.37–3.24 (m, 1H), 2.91–
2.72 (m, 2H), 2.68–2.48 (m, 1H), 2.17–2.08 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 207.3, 207.0, 152.9, 152.8, 141.2, 140.9, 140.3, 140.2, 139.4, 137.9, 
136.3, 136.2, 134.95, 134.92, 130.4 (q, J = 308.5 Hz), 130.3 (q, J = 308.8 Hz), 128.8, 127.99, 127.96, 127.7, 
127.60, 127.56, 127.52, 127.47, 127.01, 126.99, 126.44, 126.37, 124.0, 123.9, 47.59–47.54, 47.47–47.42, 
45.0, 44.8, 38.6, 37.9, 33.2, 32.5. 
19F NMR (282 MHz, CDCl3) δ -39.6, -39.7 (s, 3F). 
FT-IR (film): 3031, 2928, 1712, 1609, 1487, 1279, 1112, 742 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C24H19F3OSNa+: 435.1001, found: 435.1001. 
 
 
 
4-([1,1'-Biphenyl]-4-yl)-N,N-diethyl-2,2-difluoro-4-((trifluoromethyl)thio)butanamide.  
Table 3, entry 7.  The title compound was synthesized according to the General Procedure, using 
CuI (9.5 mg, 0.050 mmol), binap (31 mg, 0.050 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), 
NMe4SCF3 (131 mg, 0.75 mmol), and 2-bromo-N,N-diethyl-2,2-difluoroacetamide (173 mg, 0.75 
mmol) in acetonitrile (15 mL), and purified by column chromatography (4%→7% ethyl 
acetate/hexanes).  Colorless oil.  First run: 190 mg (88%).  Second run: 196 mg (91%). 
1H NMR (400 MHz, CDCl3) δ 7.61–7.58 (m, 4H), 7.47–7.43 (m, 4H), 7.38–7.34 (m, 1H), 4.87 (t, J = 
7.1 Hz, 1H), 3.53–3.29 (m, 4H), 3.09–2.98 (m, 2H), 1.18–1.13 (m, 6H). 
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13C NMR (101 MHz, CDCl3) δ 161.9 (t, J = 28.3 Hz), 141.0, 140.3, 138.8, 130.0 (q, J = 309.0 Hz), 
128.7, 127.8, 127.45, 127.42, 127.0, 118.0 (t, J = 257.9 Hz), 43.1–43.0 (m), 41.8 (t, J = 6.3 Hz), 41.6, 41.4 
(t, J = 22.9 Hz), 14.1, 12.2. 
19F NMR (282 MHz, CDCl3) δ -40.2 (s, 3F), -96.9–-99.8 (m, 2F). 
FT-IR (film): 2979, 2940, 1661, 1488, 1194, 1115, 757, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C21H22F5NOSNa+: 454.1234, found: 454.1237. 
 
 
 
Ethyl 4-([1,1'-biphenyl]-4-yl)-2,2-dimethyl-4-((trifluoromethyl)thio)butanoate.  Table 3, 
entry 8.  The title compound was synthesized according to the General Procedure, using CuI (19 
mg, 0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), NMe4SCF3 (262 
mg, 1.50 mmol), and methyl 2-bromo-2-methylpropanoate (272 mg, 1.50 mmol) in acetonitrile (15 
mL), and purified by column chromatography (3%→6% ethyl acetate/hexanes).  White solid.  
First run: 126 mg (66%).  Second run: 122 mg (64%). 
1H NMR (400 MHz, CDCl3) δ 7.60–7.55 (m, 4H), 7.47–7.42 (m, 2H), 7.39–7.33 (m, 3H), 4.46 (dd, J 
= 9.2, 5.3 Hz, 1H), 3.36 (s, 3H), 2.44 (dd, J = 14.4, 9.2 Hz, 1H), 2.29 (dd, J = 14.4, 5.3 Hz, 1H), 1.26 (s, 
3H), 1.19 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 176.7, 140.8, 140.3, 139.2, 130.2 (q, J = 308.8 Hz), 128.8, 128.2, 127.5, 
127.3, 127.0, 51.6, 46.6, 46.34–46.29, 41.9, 26.1, 25.2. 
19F NMR (282 MHz, CDCl3) δ -40.2 (s, 3F). 
FT-IR (film): 3030, 2978, 1732, 1488, 1199, 1112, 766, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C20H21F3O2SNa+: 405.1107, found: 405.1106. 
 
 
 
(1-([1,1'-Biphenyl]-4-yl)-3,3,3-trifluoropropyl)(trifluoromethyl)sulfane.  Table 3, entry 9.  
The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), NMe4SCF3 (131 mg, 0.75 
mmol), and DMSO-trifluoromethyl iodide adduct (CF3I•2SO(CH3)2, 264 mg, 0.75 mmol) in 
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acetonitrile (15 mL), and purified by column chromatography (1%→3% ethyl acetate/hexanes).  
White solid.  First run: 133 mg (76%).  Second run: 130 mg (74%). 
1H NMR (400 MHz, CDCl3) δ 7.65–7.59 (m, 4H), 7.49–7.44 (m, 2H), 7.42–7.36 (m, 3H), 4.69 (dd, J 
= 8.8, 5.8 Hz, 1H), 3.04–2.86 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 141.7, 140.1, 136.6, 129.8 (q, J = 309.3 Hz), 128.8, 127.8, 127.68, 
127.65, 127.1, 124.8 (q, J = 279.3 Hz), 42.7, 40.9 (q, J = 28.7 Hz). 
19F NMR (282 MHz, CDCl3) δ -40.3 (s, 3F), -63.9 (t, J = 9.6 Hz, 3F). 
FT-IR (film): 3055, 1488, 1375, 1265, 1247, 1113, 741, 703 cm–1. 
MS (EI) m/z (M)+ calcd for C16H12F6S+: 350.1, found: 350.1. 
 
 
 
(1-([1,1'-Biphenyl]-4-yl)-3,3,4,4,5,5,5-heptafluoropentyl)(trifluoromethyl)sulfane.  Table 3, 
entry 10.  The title compound was synthesized according to the General Procedure, using CuI (9.5 
mg, 0.050 mmol), binap (31 mg, 0.050 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), NMe4SCF3 (131 
mg, 0.75 mmol), and heptafluoro-3-iodopropane (222 mg, 0.75 mmol) in acetonitrile (15 mL), and 
purified by column chromatography (1%→3% ethyl acetate/hexanes).  Pale-yellow solid.  First 
run: 182 mg (81%).  Second run: 176 mg (78%). 
1H NMR (500 MHz, CDCl3) δ 7.65–7.59 (m, 4H), 7.48–7.45 (m, 2H), 7.44–7.41 (m, 2H), 7.40–7.37 
(m, 1H), 4.82 (dd, J = 9.2, 5.0 Hz, 1H), 3.04–2.86 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 141.7, 140.1, 137.0, 129.8 (q, J = 309.0 Hz), 128.8, 127.9, 127.7, 127.6, 
127.1, 119.0–114.0 (m, 2C), 111.0–105.9 (m), 41.7, 37.5 (t, J = 20.8 Hz). 
19F NMR (282 MHz, CDCl3) δ -40.5 (s, 3F), -80.4 (t, J = 9.7 Hz, 3F), -112.2–-115.4 (m, 2F), -127.7–-
127.8 (m, 2F). 
FT-IR (film): 3033, 1488, 1354, 1233, 1168, 1115, 960, 695 cm–1. 
MS (EI) m/z (M)+ calcd for C18H12F10S+: 450.1, found: 450.1. 
 
 
 
(1-([1,1'-Biphenyl]-4-yl)-4-chloro-3,3,4,4-tetrafluorobutyl)(trifluoromethyl)sulfane.  Table 3, 
entry 11.  The title compound was synthesized according to the General Procedure, using CuI (9.5 
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mg, 0.050 mmol), binap (31 mg, 0.050 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), NMe4SCF3 (131 
mg, 0.75 mmol), and (1-chloro)tetrafluoro-2-iodoethane (197 mg, 0.75 mmol) in acetonitrile (15 
mL), and purified by column chromatography (1%→3% ethyl acetate/hexanes).  White solid.  
First run: 179 mg (86%).  Second run: 173 mg (83%). 
1H NMR (500 MHz, CDCl3) δ 7.64–7.57 (m, 4H), 7.48–7.40 (m, 4H), 7.39–7.36 (m, 1H), 4.82–4.79 
(m, 1H), 3.03–2.86 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 141.6, 140.1, 137.1, 129.8 (q, J = 309.0 Hz), 128.8, 127.8, 127.7, 127.6, 
127.1, 125.8–120.5 (m), 118.0–113.4 (m), 42.1, 37.5 (t, J = 21.1 Hz). 
19F NMR (282 MHz, CDCl3) δ -40.4 (s, 3F), -71.6 (s, 2F), -111.1–-112.1 (m, 1F), -113.2–-114.2 (m, 
1F). 
FT-IR (film): 3032, 2927, 1488, 1412, 1276, 1093, 940, 732 cm–1. 
MS (EI) m/z (M)+ calcd for C17H12ClF7S+: 416.0, found: 416.1. 
 
 
 
(1-([1,1'-Biphenyl]-4-yl)-4,4,4-trifluorobutyl)(trifluoromethyl)sulfane.  Table 3, entry 12.  
The title compound was synthesized according to the General Procedure, using CuI (9.5 mg, 0.050 
mmol), binap (31 mg, 0.050 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), NMe4SCF3 (131 mg, 0.75 
mmol), and 1,1,1-trifluoro-2-iodoethane (158 mg, 0.75 mmol) in acetonitrile (15 mL), and purified 
by column chromatography (1%→3% ethyl acetate/hexanes).  White solid.  First run: 172 mg 
(95%).  Second run: 161 mg (88%). 
1H NMR (500 MHz, CDCl3) δ 7.63–7.59 (m, 4H), 7.48–7.45 (m, 2H), 7.40–7.36 (m, 3H), 4.38 (dd, J 
= 9.0, 6.5 Hz, 1H), 2.40–2.24 (m, 2H), 2.23–2.04 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 141.5, 140.2, 137.7, 130.2 (q, J = 308.4 Hz), 128.9, 127.8, 127.7, 127.6, 
127.1, 126.5 (q, J = 277.2 Hz), 47.9, 31.6 (q, J = 29.3 Hz), 29.1. 
19F NMR (282 MHz, CDCl3) δ -39.8 (s, 3F), -66.0 (t, J = 10.4 Hz, 3F). 
FT-IR (film): 3031, 2930, 1454, 1391, 1259, 1108, 753, 693 cm–1. 
MS (EI) m/z (M)+ calcd for C17H14F6S+: 364.1, found: 364.1. 
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(1-([1,1'-Biphenyl]-4-yl)-3-(phenylsulfonyl)propyl)(trifluoromethyl)sulfane.  Table 3, entry 
13.  The title compound was synthesized according to the General Procedure, using CuI (19 mg, 
0.10 mmol), binap (62 mg, 0.10 mmol), 4-vinylbiphenyl (90 mg, 0.50 mmol), 
bromomethylphenylsulfone (176 mg, 0.75 mmol), and NMe4SCF3 (131 mg, 0.75 mmol) in 
acetonitrile (60 mL), and purified by column chromatography (5%→14% ethyl acetate/hexanes).  
White solid.  First run: 192 mg (88%).  Second run: 187 mg (86%). 
1H NMR (400 MHz, CDCl3) δ 7.91–7.88 (m, 2H), 7.71–7.67 (m, 1H), 7.61–7.55 (m, 6H), 7.48–7.43 
(m, 2H), 7.39–7.35 (m, 1H), 7.31–7.28 (m, 2H), 4.46 (dd, J = 9.4, 6.4 Hz, 1H), 3.18–3.01 (m, 2H), 2.55–
2.37 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 141.5, 140.0, 138.6, 137.0, 134.0, 130.0 (q, J = 309.0 Hz), 129.4, 128.8, 
128.0, 127.8, 127.69, 127.66, 127.0, 53.5, 47.2, 29.6. 
19F NMR (282 MHz, CDCl3) δ -39.7 (s, 3F). 
FT-IR (film): 3032, 2927, 1487, 1448, 1307, 1152, 1112, 689 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C22H19F3O2S2Na+: 459.0671, found: 459.0675. 
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III.  Three-Component Couplings with Other Nucleophiles 
 
CuI (9.5 mg, 0.050 mmol) and binap (31 mg, 0.050 mmol) were added to a 20-mL borosilicate 
glass vial that contained a magnetic stir bar.  The vial was capped with a PTFE-lined septum cap 
(the joint was wrapped with electric tape), and then it was evacuated and backfilled with nitrogen 
(3 cycles).  Next, a solution of tetra-n-butylammonium bromide (242 mg, 0.75 mmol) in dry 
acetonitrile (15 mL), allylbenzene (59 mg, 0.50 mmol), and ethyl bromodifluoroacetate (152 mg, 
0.75 mmol) were added in sequence via syringe, and the mixture was stirred at room temperature 
for 5 min.  The vial was then detached from the Schlenk line, and the puncture holes in the 
septum were covered with vacuum grease and electric tape.  After blue-LED irradiation and 
standard workup, the carbobrominated product was purified by column chromatography 
(1%→3% ethyl acetate/hexanes) as a pale-yellow oil.  First run: 126 mg (79%).  Second run: 128 
mg (80%). 
 
Ethyl 4-bromo-2,2-difluoro-5-phenylpentanoate.  Table 4, entry 1. 
1H NMR (400 MHz, CDCl3) δ 7.37–7.27 (m, 3H), 7.23–7.17 (m, 2H), 4.38–4.28 (m, 3H), 3.30–3.17 
(m, 2H), 2.87–2.64 (m, 2H), 1.36 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.5 (t, J = 32.3 Hz), 137.2, 129.2, 128.6, 127.2, 114.8 (dd, J = 253.6, 
250.0 Hz), 63.2, 45.6, 45.4 (dd, J = 5.9, 3.5 Hz), 42.6 (dd, J = 24.6, 23.1 Hz), 13.8. 
19F NMR (282 MHz, CDCl3) δ -101.1 (dt, J = 264.9, 13.8 Hz, 1F), -107.1 (ddd, J = 264.8, 19.0, 15.2 
Hz, 1F). 
FT-IR (film): 3030, 2985, 1771, 1375, 1304, 1191, 1092, 701 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C13H15BrF2O2Na+: 343.0116, found: 343.0113. 
 
 
CuI (22.8 mg, 0.12 mmol), binap (74.6 mg, 0.12 mmol), and 4-vinylbiphenyl (108 mg, 0.60 mmol) 
were added to a 20-mL borosilicate glass vial that contained a magnetic stir bar.  The vial was 
capped with a PTFE-lined septum cap (the joint was wrapped with electric tape), and then it was 
evacuated and backfilled with nitrogen (3 cycles).  Next, a solution of tetra-n-butylammonium 
cyanide (241 mg, 0.90 mmol) in dry acetonitrile (18 mL) and ethyl bromodifluoroacetate (182 mg, 
0.90 mmol) were added in sequence via syringe, and the mixture was stirred at room temperature 
for 5 min.  The vial was then detached from the Schlenk line, and the puncture holes in the 
septum were covered with vacuum grease and electric tape.  After blue-LED irradiation and 
standard workup, the carbocyanated product was purified by column chromatography (1:1→3:1 
toluene/hexanes) as a white solid.  First run: 103 mg (52%).  Second run: 110 mg (56%). 
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Ethyl 4-([1,1'-biphenyl]-4-yl)-4-cyano-2,2-difluorobutanoate.  Table 4, entry 2. 
1H NMR (400 MHz, CDCl3) δ 7.65–7.62 (m, 2H), 7.59–7.56 (m, 2H), 7.48–7.44 (m, 4H), 7.41–7.36 
(m, 1H), 4.34–4.23 (m, 2H), 4.17 (dd, J = 9.3, 5.1 Hz, 1H), 2.95–2.82 (m, 1H), 2.71–2.58 (m, 1H), 1.35 (t, 
J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 162.8 (t, J = 31.9 Hz), 141.9, 139.9, 132.9, 128.9, 128.1, 127.80, 
127.78, 127.1, 119.1, 113.8 (t, J = 252.9 Hz), 63.5, 40.1 (t, J = 23.9 Hz), 30.4 (t, J = 4.8 Hz), 13.8. 
19F NMR (282 MHz, CDCl3) δ -105.1–-105.3 (s, 2F). 
FT-IR (film): 3032, 2987, 2246, 1770, 1488, 1309, 1196, 1092, 764 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C19H17F2NO2Na+: 352.1120, found: 352.1121. 
 
 
CuI (22.8 mg, 0.12 mmol), binap (74.6 mg, 0.12 mmol), and 4-vinylbiphenyl (108 mg, 0.60 mmol) 
were added to a 20-mL borosilicate glass vial that contained a magnetic stir bar.  The vial was 
capped with a PTFE-lined septum cap (the joint was wrapped with electric tape), and then it was 
evacuated and backfilled with nitrogen (3 cycles).  Next, a solution of tetra-n-butylammonium 
azide (256 mg, 0.90 mmol) in dry acetonitrile (18 mL) and 1,1,1-trifluoro-2-iodoethane (189 mg, 0.90 
mmol) were added in sequence via syringe, and the mixture was stirred at room temperature for 5 
min.  The vial was then detached from the Schlenk line, and the puncture holes in the septum 
were covered with vacuum grease and electric tape.  After blue-LED irradiation and standard 
workup, the carboazidated product was purified by column chromatography (1%→2% ethyl 
acetate/hexanes) as a white solid.  First run: 119 mg (65%).  Second run: 117 mg (64%). 
 
4-(1-Azido-4,4,4-trifluorobutyl)-1,1'-biphenyl.  Table 4, entry 3. 
1H NMR (400 MHz, CDCl3) δ 7.66–7.59 (m, 4H), 7.48–7.44 (m, 2H), 7.40–7.36 (m, 3H), 4.58 (dd, J 
= 7.8, 6.0 Hz, 1H), 2.33–1.98 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 141.7, 140.3, 137.2, 128.8, 127.8, 127.6, 127.2, 127.1, 126.8 (q, J = 
277.2 Hz), 64.5, 30.7 (q, J = 29.3 Hz), 28.9 (q, J = 2.9 Hz). 
19F NMR (282 MHz, CDCl3) δ -66.07 (t, J = 10.4 Hz, 3F). 
FT-IR (film): 2959, 2103, 1452, 1244, 1133, 998, 765, 692 cm–1. 
MS (EI) m/z (M)+ calcd for C16H14F3N3+: 305.1, found: 305.1.  
 S–23 
IV.  Functional-Group Tolerance 
 
Table 4.  In a nitrogen-filled glovebox, CuI (3.8 mg, 0.020 mmol), binap (12.4 mg, 0.020 mmol), 
NMe4SCF3 (52.5 mg, 0.30 mmol), allylbenzene (23.6 mg, 0.20 mmol), ethyl bromodifluoroacetate 
(60.9 mg, 0.30 mmol), anhydrous acetonitrile (6 mL) were added sequentially to an oven-dried 8-
mL vial.  Next, the additive (0.20 mmol) was added, and the vial was capped and subjected to 
irradiation with blue-LED lamp for 10 h.  An internal standard (n-dodecane) was then added into 
the reaction mixture, and it was filtered through a PTFE syringe filter.  The unpurified reaction 
mixture was analyzed via GC. 
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V.  Less Effective Electrophiles 
 
Following General Procedure, less effective electrophiles are listed below: 
 
 
Table S1.  Less effective electrophiles. 
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VI.  Other Olefin Substrates 
 
Following General Procedure, other olefin substrates are listed below: 
 
 
Table S2.  Other substrates. 
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VII.  Mechanistic Studies 
 
 
 
Complex 1 (eq 2).  To a solution of CuI (38 mg, 0.20 mmol, 1.0 equiv) in dry and degassed 
acetonitrile (3.0 mL) was added AgSCF3 (42 mg, 0.20 mmol, 1.0 equiv) in acetonitrile (1.0 mL) 
under N2 atmosphere, and the mixture was vigorously stirred at room temperature for 30 min.  
Next, the mixture was filtered through a PTFE syringe filter to remove AgI and then washed by 
acetonitrile (1.0 mL) to get a clear solution in a 40-mL scintillation vial.  Binap (124 mg, 0.20 mmol, 
1.0 equiv) in acetonitrile (20 mL) was carefully added to this solution, and the resulting mixture 
was vigorously stirred overnight at room temperature.  Upon removal of solvents in vacuo, the 
desired product was obtained as a pale yellow solid (156 mg, 99% yield).  Crystals suitable for 
single-crystal X-ray diffraction were grown by slow evaporation of a concentrated sample in 
dichloromethane at room temperature. 
1H NMR (400 MHz, CD2Cl2) δ 7.90–7.84 (m, 8H), 7.54–7.47 (m, 20H), 7.34–7.30 (m, 4H), 7.17–7.12 
(m, 12H), 7.09–7.05 (m, 4H), 6.78–6.76 (m, 4H), 6.74–6.70 (m, 4H), 6.57–6.54 (m, 8H). 
13C NMR (101 MHz, CD2Cl2) δ 138.8 (virtual triplet, JPC = 17.0 Hz), 137.4 (q, JFC = 302.7 Hz), 135.1 
(virtual triplet, JPC = 19.6 Hz), 133.6 (virtual triplet, JPC = 18.3 Hz), 133.4 (virtual triplet, JPC = 7.6 Hz), 
133.1, 131.4 (virtual triplet, JPC = 27.0 Hz), 131.1 (virtual triplet, JPC = 40.4 Hz), 130.8, 129.3, 129.0 
(virtual triplet, JPC = 10.9 Hz), 128.6 (virtual triplet, JPC = 7.4 Hz), 128.2–127.9, 127.36–127.25, 127.2, 
126.6, 126.3. 
19F NMR (282 MHz, CD2Cl2) δ -20.6 (s, 6F). 
31P NMR (121 MHz, CD2Cl2) δ 1.83. 
Anal. Calcd for C90H64Cu2F6P4S2: C, 68.65; H, 4.10.  Found: C, 68.42; H, 4.43. 
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Table S3.  Crystal data and structure refinement for copper complex 1. 
 
          
 
Identification code Complex 1 
Empirical formula C90H64Cu2F6P4S2 
Formula weight 1574.49 
Temperature/K 100(2) 
Crystal system Triclinic 
Space group P-1 
a/Å 11.1442(12) 
b/Å 12.9041(13) 
c/Å 13.9829(14) 
a/° 101.643(4) 
b/° 97.123(4) 
g/° 109.481(4) 
V/Å3 1816.4(3) 
Z 1 
r/g/cm-3 1.439 
m/mm-1 0.795 
F(000) 808.0 
Crystal size/mm3 0.21 × 0.18 × 0.14 
Radiation MoKα (λ = 0.71073) 
2θ range for data collection/° 4.194 to 84.21 
Index ranges -21 ≤ h ≤ 21, -24 ≤ k ≤ 24, -26 ≤ l ≤ 26 
Independent reflections 200649 
Data/restraints/parameters 25546 [Rint = 0.0486, Rsigma = 0.0336] 
Goodness-of-fit on F2 1.055 
R [I>=2θ (I)] (R1, wR2) R1 = 0.0405, wR2 = 0.1041 
R (all data) (R1, wR2) R1 = 0.0618, wR2 = 0.1151 
Largest diff. peak/hole/(e Å-3) 2.45/-0.73 
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Additional details.  This crystal structure contained residual electron density assignable to a 
disordered CH2Cl2 molecule.  OLEX2 was used to identify voids and a solvent mask was applied 
[Void volume = 113.6 Å3 corresponding to 23.0 electrons].  This application gave a good 
improvement of data statistics. 
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Figure S2.  Emission spectra (excitation at 350 nm) in acetonitrile of: [(binap)Cu(SCF3)]2 (0.042 
mM), blue trace; [(binap)Cu(SCF3)]2 (0.042 mM) + ethyl bromodifluoroacetate (50 mM), red trace. 
Addition of ethyl bromodifluoroacetate quenches the emission. 
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Figure S3.  X-band EPR spectra (9.4 GHz, 40 K) of the model reaction in Table 1: 10 min at -40 
°C, blue trace; 10 min at r.t., red trace; 60 min at r.t., yellow trace. 
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Figure S4.  Zoomed-in X-band EPR spectra (9.4 GHz, 40 K) of the model reaction in Table 1 at 
r.t.: 10 min, blue trace; 60 min, red trace. 
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The reaction mixture in the following table was prepared in a nitrogen-filled glovebox.  The 
mixture was then subjected to various reaction conditions for 10 h, and it was filtered through a 
short plug of silica gel (rinsed with ethyl acetate).  The recovery of the electrophile was 
determined via 19F NMR analysis using PhCF3 as an internal standard. 
 
Table S4.  Control experiments without the alkene. 
 
 
  
 S–33 
The reaction mixture in the following table was prepared in a nitrogen-filled glovebox.  The 
mixture was then subjected to various reaction conditions for 10 h, and it was filtered through a 
short plug of silica gel (rinsed with ethyl acetate).  The recovery of the electrophile was 
determined via 19F NMR analysis using PhCF3 as an internal standard.  Next, the reaction mixture 
was concentrated under vacuum, and the yield of the carbobrominated product was determined 
via 1H NMR analysis using CH2Br2 as an internal standard. 
 
Table S5.  Control experiments with allylbenzene. 
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Eq 5.  CuI (9.5 mg, 0.050 mmol) and binap (31 mg, 0.050 mmol) were added to a 20-mL 
borosilicate glass vial that contained a magnetic stir bar.  The vial was capped with a PTFE-lined 
septum cap (the joint was wrapped with electric tape), and then it was evacuated and backfilled 
with nitrogen (3 cycles).  Next, a solution of NMe4SCF3 (131 mg, 0.75 mmol) and (2,2,6,6-
tetramethylpiperidin-1-yl)oxyl (TEMPO) (78 mg, 0.50 mmol) in dry acetonitrile (15 mL), 
allylbenzene (59 mg, 0.50 mmol), and ethyl bromodifluoroacetate (152 mg, 0.75 mmol) were added 
in sequence via syringe, and the mixture was stirred at room temperature for 5 min.  The vial was 
then detached from the Schlenk line, and the puncture holes in the septum were covered with 
vacuum grease and electric tape.  After blue-LED irradiation and standard workup, the TEMPO-
adduct was purified by column chromatography (0%→2% Et2O/hexanes) as a colorless oil.  First 
run: 46 mg (33%).  Second run: 43 mg (31%). 
 
Ethyl 2,2-difluoro-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)acetate.  [1620563-59-8]. 
1H NMR (400 MHz, CDCl3) δ 4.35 (q, J = 7.1 Hz, 2H), 1.67–1.50 (m, 5H), 1.38–1.32 (m, 4H), 1.19–
1.16 (m, 12H). 
13C NMR (101 MHz, CDCl3) δ 160.7 (t, J = 42.7 Hz), 115.5 (t, J = 272.5 Hz), 63.0, 61.4, 40.2, 33.4 (t, J 
= 4.4 Hz), 20.7, 16.9, 13.9. 
19F NMR (282 MHz, CDCl3) δ -73.49–-73.53 (m, 2F). 
FT-IR (film): 2981, 2940, 1775, 1467, 1325, 1247, 1134, 860 cm–1. 
MS (ESI) m/z (M+H)+ calcd for C13H24F2NO3+: 280.1719, found: 280.1726. 
 
 
Eq 6.  In a nitrogen-filled glovebox, CuI (5.7 mg, 0.030 mmol), binap (18.7 mg, 0.030 mmol), 
NMe4SCF3 (78.8 mg, 0.45 mmol), trans-(1-(2-phenylcyclopropyl)vinyl)benzene (66.0 mg, 0.30 
mmol), ethyl bromodifluoroacetate (91.4 mg, 0.45 mmol), and anhydrous acetonitrile (9 mL) were 
added sequentially to an oven-dried 20-mL vial.  Next, the vial was capped, removed from the 
glovebox, and subjected to irradiation with blue-LED lamp for 10 h.  After standard workup, the 
ring-opening product was purified by column chromatography (0%→5% Et2O/hexanes) as a 
colorless oil.  First run: 109.2 mg (82%), 2.48:1 E/Z ratio.  Second run: 111.9 mg (84%), 2.52:1 E/Z 
ratio. 
 
Ethyl 2,2-difluoro-4,7-diphenyl-7-((trifluoromethyl)thio)hept-4-enoate. 
1H NMR (400 MHz, CDCl3) δ 7.41–7.27 (m, 7.5H), 7.25–7.19 (m, 2H), 7.04–7.00 (m, 0.58H), 5.79 (t, 
J = 7.3 Hz, 0.71H), 5.62 (t, J = 7.2 Hz, 0.29H), 4.47 (dd, J = 8.4, 6.8 Hz, 0.70H), 4.32 (dd, J = 8.3, 6.9 Hz, 
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0.29H), 3.97 (q, J = 7.2 Hz, 0.59H), 3.89 (q, J = 7.2 Hz, 1.42H), 3.34–3.08 (m, 2H), 3.04–2.86 (m, 1.42H), 
2.74–2.57 (m, 0.61H), 1.19–1.13 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.6 (t, J = 32.5 Hz), 163.5 (t, J = 32.7 Hz), 141.5, 139.7, 139.5, 138.4, 
134.4 (t, J = 4.6 Hz), 133.1 (t, J = 4.1 Hz), 130.8, 130.4 (t, J = 308.5 Hz), 130.3 (t, J = 308.6 Hz), 129.5, 
128.8, 128.7, 128.3, 128.2, 128.1, 128.0, 127.55, 127.46, 127.42, 126.8, 114.89 (t, J = 253.5 Hz), 114.88 (t, J 
= 252.2 Hz), 62.7, 62.6, 49.3–49.2, 43.9 (t, J = 24.0 Hz), 36.2, 36.0, 35.6 (t, J = 24.6 Hz), 13.7, 13.5. 
19F NMR (282 MHz, CDCl3) δ -39.8 (s), -39.9 (s), -103.0–-103.2 (m), -103.5–-103.7 (m). 
FT-IR (film): 3062, 3034, 2924, 2852, 1768, 1493, 1455, 1223, 755, 698 cm–1. 
MS (ESI) m/z (M+Na)+ calcd for C22H21F5NaO2S+: 467.1075, found: 467.1079. 
 
 
Following General Procedure, 4-penten-1-ol was tested in the three-component coupling 
reaction.  Since the cyclized product was not observed, the carbocation pathway is unlikely in 
terms of aliphatic olefin substrates. 
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